Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.56 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.56 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8777872 | 0.87 | KMT2A (0.65) | KMT2ACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL8685580 | 0.86 | CHRM1 (0.56) | KMT2ACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL6901583 | 0.86 | KMT2A (0.63) | KMT2ACHRM2CHRM4CHRM5CHRM1 | |
| Hydrochloric Acid SCHEMBL8685563 | 0.86 | KMT2A (0.68) | KMT2ACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL8775260 | 0.84 | CHRM1 (0.73) | KMT2ACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL8775364 | 0.84 | KMT2A (0.61) | KMT2ACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL8649491 | 0.83 | KMT2A (0.60) | KMT2ACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL8648529 | 0.83 | KMT2A (0.60) | KMT2ACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL8645430 | 0.83 | KMT2A (0.60) | KMT2ACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL8644761 | 0.83 | KMT2A (0.60) | KMT2ACHRM2CHRM4CHRM5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0569564-B1 | BIPHENYLYLQUINUCLIDINES, USEFUL AS SQUALENE SYNTHETASE INHIBITORS | ZENECA LTD (GB) | 1997-12-29 | — | — | EP | claimed |
| EP-0569564-A1 | BIPHENYLYLQUINUCLIDINES, USEFUL AS SQUALENE SYNTHETASE INHIBITORS | ZENECA LIMITED (GB) | 1993-11-18 | — | — | EP | claimed |
| WO-1993009115-A1 | BIPHENYLYLQUINUCLIDINES, USEFUL AS SQUALENE SYNTHETASE INHIBITORS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-05-13 | — | — | WO | claimed |
| US-20160375041-A1 | INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT AUTOIMMUNE DISORDERS | TABACZYNSKI DAVID A (US) | 2016-12-29 | — | — | US | disclosed |
| US-20160303146-A1 | INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT NEUROINFLAMMATORY DISORDERS | TABACZYNSKI DAVID A (US) | 2016-10-20 | — | — | US | disclosed |
| WO-2015089349-A1 | INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT NEUROINFLAMMATORY DISORDERS | TABACZYNSKI DAVID A (US) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015084721-A1 | INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT AUTOIMMUNE DISORDERS | TABACZYNSKI DAVID A (US) | 2015-06-11 | — | — | WO | disclosed |
| US-20080119483-A1 | COMPOSITIONS AND METHODS FOR INHIBITING PROTOZOAN GROWTH | WASHINGTON UNIVERSITY IN ST. LOUIS (US) | 2008-05-22 | — | — | US | disclosed |
| US-5792777-A | SQUALENE SYNTHASE INHIBITORS, USEFUL IN TREATING HYPERCHOLESTEROLEMIA, ATHEROSCLEROSIS AND FUNGAL DISEASES | ZENECA LIMITED (GB) | 1998-08-11 | — | — | US | disclosed |
| EP-0569564-B1 | BIPHENYLYLQUINUCLIDINES, USEFUL AS SQUALENE SYNTHETASE INHIBITORS | ZENECA LTD (GB) | 1997-12-29 | — | — | EP | disclosed |
| EP-0569564-A1 | BIPHENYLYLQUINUCLIDINES, USEFUL AS SQUALENE SYNTHETASE INHIBITORS | ZENECA LIMITED (GB) | 1993-11-18 | — | — | EP | disclosed |
| WO-1993009115-A1 | BIPHENYLYLQUINUCLIDINES, USEFUL AS SQUALENE SYNTHETASE INHIBITORS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160375041-A1 | INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT AUTOIMMUNE DISORDERS | GGPS1, FDPS, COASY | KMT2A 4161/4885CHRM2 4276/4885CHRM4 3858/4885 |
| US-20160303146-A1 | INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT NEUROINFLAMMATORY DISORDERS | GGPS1, FDPS, COASY | KMT2A 4620/4885CHRM2 4206/4885CHRM4 3398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.